Tesamorelin in Women: Sex-Specific Research Protocols for UAE (2026)

Why Women Were Under-Studied in the Tesamorelin Trials

Tesamorelin reached the FDA in 2010 on the back of two pivotal Phase III trials run by Falutz and colleagues (NEJM 2007; JAIDS 2010). Both were conducted in HIV-positive adults with central lipodystrophy — a population that, in North America in the mid-2000s, skewed roughly 85% male. The pooled enrolment of ~800 subjects included only ~120 women, and the trials were powered for the combined population, not for sex-specific endpoints.

The result: tesamorelin's label-driving evidence is overwhelmingly male. Women were included, the drug worked in them, but the dose-response curve, IGF-1 kinetics, and side-effect profile in female subjects were not the primary focus of any pivotal trial. This created a long-standing gap that Stanley 2014 (JCEM) was the first to address with a formal sex subgroup analysis.

Stanley 2014 — The Sex Subgroup Analysis That Matters

Steven Grinspoon's group at Massachusetts General Hospital pooled the two Falutz Phase III datasets and performed a pre-specified sex subgroup analysis (Stanley TL et al., J Clin Endocrinol Metab 2014). Key findings:

The headline conclusion: tesamorelin works in women at the same 2 mg/day SC dose, but the IGF-1 axis response is meaningfully blunted. Women generated roughly 58% of the IGF-1 elevation men did from the same dose — likely reflecting baseline differences in growth hormone binding protein, oestrogen-modulated hepatic IGF-1 production, and somatostatinergic tone.

Sex-Specific Dosing Considerations

The 2 mg/day Standard Holds — For Now

Despite the blunted IGF-1 response, Stanley 2014 did not recommend dose escalation in women. The reason is mechanistic: tesamorelin's clinical effect on VAT is driven by restored GH pulsatility, not by sustained IGF-1 elevation. Women hit the VAT endpoint at 2 mg/day even with lower IGF-1 amplitude, suggesting the GH pulse architecture matters more than the integrated IGF-1 area-under-curve.

What This Means For Research Protocols

• Keep the dose at 2 mg/day SC in female subjects — escalating to 3 or 4 mg/day adds side-effect burden without proportionate VAT benefit in the published data.
• Track VAT, not IGF-1, as the primary endpoint. IGF-1 in women on tesamorelin will underestimate the GH-axis effect.
• Extend study duration to 26+ weeks. The 20-week early-readout windows used in male-dominant trials will under-capture the female response curve.
• Pre-menopausal vs post-menopausal stratification matters. Oestrogen modulates hepatic IGF-1 production directly; pooling pre- and post-menopausal women obscures the signal.

Menstrual Cycle Effects on the GH-IGF-1 Axis

Endogenous growth hormone pulsatility is not constant across the menstrual cycle. Faria et al. (J Clin Endocrinol Metab 1992) and subsequent work showed:

• Late follicular phase (days 10–14): peak GH pulse amplitude, driven by rising oestradiol
• Mid-luteal phase (days 20–24): moderate amplitude, progesterone-stabilised
• Early follicular phase (days 1–5): lowest amplitude, low sex steroids

Tesamorelin (a GHRH analogue) acts by amplifying endogenous GH pulses, so the same 2 mg dose theoretically produces a larger absolute GH response in the late follicular window than in early follicular. In practice, this variability is averaged out across multi-week dosing, but it has two implications for research:

1. IGF-1 sampling timing matters. Always sample at the same cycle phase across visits, or normalise to cycle day.
2. Single-dose pharmacodynamic studies should specify cycle phase. Otherwise you confound the drug effect with endogenous cycle variance.

For chronic dosing (the standard 26-week VAT protocol), no cycle-phase adjustment is needed. The drug is dosed daily, the IGF-1 axis reaches a new steady state within 2–3 weeks, and cycle-driven oscillations become noise rather than signal.

The Falutz HIV Trials — What Women Actually Got

Looking back at the foundational evidence with a female-specific lens:

Falutz 2007 (NEJM) enrolled 412 subjects, of whom 59 were women. At week 26, women in the tesamorelin arm achieved a 15.0% VAT reduction vs +5.0% in placebo — a treatment effect of ~20 percentage points, slightly larger than the male treatment effect. The catch: IGF-1 rose only ~40% in women vs ~85% in men.

Falutz 2010 (JAIDS) was the 6-month extension trial, enrolling 404 subjects, of whom ~80 were women. VAT reduction was maintained at week 52 in continuing-treatment subjects of both sexes. Notably, women who switched from placebo to tesamorelin at week 26 caught up to the originally-treated group within 12 weeks — confirming the drug works on the female VAT depot identically, just with different IGF-1 amplitude.

Stanley 2012 (JAMA) — a separate Grinspoon-group trial in non-HIV obese women — tested tesamorelin 2 mg/day for 6 months in 60 women with abdominal obesity. Result: 14% VAT reduction vs placebo, comparable to the HIV trial effect, with IGF-1 elevation again blunted relative to historical male data. This was the first dedicated female-only tesamorelin trial and confirmed the drug works outside the HIV context.

Side-Effect Profile in Women

The Stanley 2014 sex subgroup found a slightly higher discontinuation rate in women (11.4% vs 9.2% in men). The driver was not new side effects but exaggeration of common ones:

• Injection-site reactions: more frequently reported by female subjects (likely a reporting-rate artefact rather than biological)
• Arthralgia / fluid retention: appeared at similar absolute frequency but was rated more bothersome on quality-of-life instruments
• Paraesthesia: minor numerical excess in women, no statistical difference
• Hyperglycaemia: identical in both sexes — tesamorelin's mild glucose effect is sex-independent

For a deeper look at side-effect mitigation across all populations, see our tesamorelin side-effects mitigation guide.

Where to Buy Tesamorelin in the UAE — REVIVE LAB Stock & 24h Delivery

REVIVE LAB holds tesamorelin in Dubai stock and is the fastest source in the UAE for research-grade material. We supply tesamorelin in two vial sizes:

24h Delivery Coverage

• Dubai: same-day if ordered before 2 PM, otherwise next-day
• Abu Dhabi: 24h delivery, dispatched from Dubai stock
• Sharjah: 24h delivery, often same-day for early orders
• Ajman, RAK, UAQ, Fujairah: 24h to next-day, cold-chain maintained

Cold-Chain Logistics

Tesamorelin lyophilised powder is stable at room temperature short-term, but REVIVE ships every vial in insulated packaging with gel packs to preserve potency through UAE summer temperatures. Once reconstituted, the vial requires refrigeration (2–8°C) and remains stable for 14 days — see our UAE peptide fridge storage guide.

Ordering Process

1. Place order via tesamorelin UAE product page
2. Receive HPLC certificate of analysis by email within 1 hour
3. Cold-chain courier dispatch from Dubai warehouse (same-day cut-off 2 PM)
4. Delivery within 24 hours to any UAE emirate
5. Reconstitution support via WhatsApp on request

For the broader product range and additional peptides, browse the full REVIVE peptides UAE catalogue.

Practical Female-Specific Protocol Template

For researchers designing a female-cohort tesamorelin study, the Stanley 2014 data supports this template:

1. Dose: 2 mg subcutaneous daily, evening administration
2. Duration: minimum 26 weeks for VAT endpoint, 52 weeks preferred
3. Stratification: pre-menopausal vs post-menopausal at enrolment
4. Primary endpoint: VAT change by CT or MRI at week 26 and 52
5. Secondary endpoints: IGF-1 (sampled mid-luteal, weeks 4, 12, 26), triglycerides, HbA1c, quality of life
6. Cycle-phase IGF-1 sampling: for pre-menopausal women, standardise to mid-luteal phase across visits
7. Safety monitoring: fasting glucose at baseline, week 12, week 26; injection-site review every visit